Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Bromides of the Ming oral solution, which is approved for production and is used to treat myasthenia gravis [1] Group 1 - The drug Bromides of the Ming oral solution was originally developed by BAUSCH and was first launched in the United States in 1965 [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601607 证券简称：上海医药 编号：临2026-001 上海医药集团股份有限公司 关于2019年A股股票期权激励计划预留股票期权第三个行权期2025年第四季度自主行权结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 上海医药集团股份有限公司（以下简称"上海医药"或"公司"）2019年A股股票期权激励计划（"本次股 权激励计划"）预留股票期权第三个行权期可行权的股票期权数量680,000份，行权期自2025年2月8日起 至2026年2月7日止。 ● 本次行权股票数量：2025年第四季度，公司预留股票期权第三个行权期激励对象未行权。 一、本次股权激励计划已履行的相关审批程序 1、2019年9月30日，公司召开第七届董事会第五次会议及第七届监事会第三次会议，审议通过了《关于 2019年股票期权激励计划（草案）及其摘要的议案》（以下简称"《股票期权激励计划（草案）》"）、 《关于2019年股票期权激励计划实施考核管理办法的议案》（以下简称 ...

证券代码：601607 证券简称：上海医药 编号：临2026-001 上海医药集团股份有限公司 关于 2019 年 A 股股票期权激励计划预留股票期权第三个行 权期 2025 年第四季度自主行权结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本次股权激励计划已履行的相关审批程序 1、2019 年 9 月 30 日，公司召开第七届董事会第五次会议及第七届监事会 第三次会议，审议通过了《关于 2019 年股票期权激励计划（草案）及其摘要的 议案》（以下简称"《股票期权激励计划（草案）》"）、《关于 2019 年股票期权激 励计划实施考核管理办法的议案》（以下简称"《考核管理办法》"）、《关于提请 股东大会授权董事会办理 2019 年股票期权激励计划相关事宜的议案》。公司董事 中作为激励对象的关联董事左敏先生、李永忠先生及沈波先生均已回避表决。公 司独立董事基于独立客观判断，发表独立意见同意上述事项；公司监事会亦出具 核查意见。详见公司于 2019 年 10 月 1 日在指定信息披露媒体发布的相关 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 1 月 6 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 编号：临2026-001 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 2019 年 A ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02607 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | -- ...

Group 1 - The acquisition involves a transfer of state-owned equity, resulting in the acquirer and its concerted parties indirectly controlling over 30% of the voting rights in the listed company, triggering the obligation to make a tender offer [2] - The acquisition is exempt from the obligation to make a tender offer as it meets the criteria set forth in the regulations regarding state-owned asset transfers [20][21] - The acquirer and its concerted parties have committed to the accuracy and completeness of the information disclosed in the acquisition report [5] Group 2 - The acquirer, Shanghai Shanshi Group, is a wholly state-owned enterprise controlled by the Shanghai State-owned Assets Supervision and Administration Commission [4] - The core business of the acquirer includes diversified operations such as equity investment, real estate development, and financial services [4] - The financial status of the acquirer over the past three years has been audited, indicating a strong financial position [38] Group 3 - The purpose of the acquisition is to optimize the management structure and enhance the core competitiveness of the acquirer in line with state-owned enterprise reform requirements [13] - The acquisition will not change the controlling shareholder or actual controller of the listed company, which remains the Shanghai State-owned Assets Supervision and Administration Commission [14] - The acquirer plans to increase its stake in the listed company by acquiring an additional 55 million to 74 million shares within the next 12 months [15] Group 4 - The acquisition process has been completed in accordance with the necessary legal procedures, including the approval from the Shanghai State-owned Assets Supervision and Administration Commission [16] - The shareholding structure of the listed company will change from 25.303% to 38.748% post-acquisition, without affecting the actual control [18] - The shares involved in the acquisition are all tradable and free from any restrictions [18] Group 5 - The funding for the acquisition is derived from a government-approved transfer of state-owned shares, with no cash payment required [19] - The acquirer has no plans to change the main business operations of the listed company within the next 12 months [21] - There are no plans for significant adjustments to the board of directors or senior management of the listed company following the acquisition [24] Group 6 - The acquisition will not impact the independence of the listed company, as it will maintain its operational autonomy [29] - There is no existing or anticipated competition between the acquirer and the listed company, ensuring no adverse effects on business operations [31] - The acquirer has committed to minimizing and regulating any future related-party transactions with the listed company [34]

除上文所披露者外，持續關連交易公告的所有其他資料維持不變。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( ) 於中華人民共和國註冊成立的股份有限公司 (股份代碼: 02607) 2026 銷售及採購框架協議 的持續關連交易最新進展 茲提述上海醫藥集團股份有限公司（「本公司」）日期為2025年12月30日的公告（「持續關連交易公 告」），內容有關本公司與雲南白藥擬訂立期限自2026年1月1日起至2026年12月31日止的2026銷售及採 購框架協議。除本公告另有界定外，本公告所用詞彙與持續關連交易公告所界定者具有相同涵義。 董事會欣然宣佈，本公司已於2025年12月31日與雲南白藥按持續關連交易公告所載的主要條款簽署了 2026銷售及採購框架協議。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 承董事會命 上海醫藥集團股份有限公司 楊秋華 中國上海，2026年1月1日 於本公告日 ...

Group 1 - The acquisition involves a transfer of state-owned equity that results in the acquirer and its concerted parties indirectly controlling more than 30% of the voting rights in the listed company, triggering the obligation to make a public offer [2] - The acquisition is exempt from the obligation to make a public offer as it falls under the conditions specified in Article 63 of the Regulations on the Takeover of Listed Companies [2][28] - The acquirer and its concerted parties have committed that the report summary does not contain any false records, misleading statements, or significant omissions, and they bear legal responsibility for its authenticity, accuracy, and completeness [2][30] Group 2 - The acquirer is a wholly state-owned enterprise controlled by the Shanghai State-owned Assets Supervision and Administration Commission, with its operational management handled by Shanghai Industrial Group [5] - The acquirer has a diversified business model, primarily focusing on investment and management, with subsidiaries engaged in equity investment, real estate development, finance, and other sectors [6] - The acquirer has not faced any administrative or criminal penalties, nor has it been involved in significant civil litigation or arbitration in the past five years [7] Group 3 - The purpose of the acquisition is to optimize the management structure and establish a mechanism for the allocation of state capital, supporting the reform of state-owned enterprises and enhancing core competitiveness [17] - The acquisition will not change the controlling shareholder or actual controller of the listed company, which remains the Shanghai State-owned Assets Supervision and Administration Commission [18] - The acquirer plans to increase its stake in Shanghai Pharmaceuticals by acquiring an additional 55 million to 74 million H-shares within the next 12 months, using its own funds [19] Group 4 - Prior to the equity adjustment, the acquirer directly held 221,801,798 shares of Shanghai Pharmaceuticals, accounting for 5.981%, and indirectly held 716,516,039 shares, totaling 25.303% [21] - After the equity adjustment, the acquirer and its concerted parties will hold a total of 38.748% of the shares in Shanghai Pharmaceuticals, maintaining the same actual controller [22][24] - The shares involved in the equity adjustment are all tradable and do not have any restrictions such as pledges or judicial freezes [25] Group 5 - The equity adjustment is a government-approved transfer of state-owned shares, and the acquirer does not need to pay any consideration for the shares acquired [26] - The report summary has been prepared in accordance with relevant laws and regulations, ensuring that all necessary information has been disclosed [29]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司收購報告書》、《上海醫藥集團股份有限公司收購報告書 摘要》、《上海市錦天城律師事務所關於<上海醫藥集團股份有限公司收購報告書>之法律意 見書》、《上海市錦天城律師事務所關於上海上實（集團）有限公司及其一致行動人免於發出 要約事宜之法律意見書》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 12 月 31 日 於本公告日期，本公司 ...

自願公告 完成控股股東股權調整 茲提述上海醫藥集團股份有限公司（「本公司」）日期為2025年10月15日的公告（「公 告」），內容有關，本公司的實際控制人上海市國資委將上實集團的全部股權調整至金鐘控 股（「本次股權調整」）。除另有界定外，本公告所用詞彙與該等公告所界定者具有相同涵 義。 於2025年12月29日，本次股權調整已根據該等公告所載結構完成。本次股權調整不會導致本 公司控股股東和實際控制人發生變化，本公司的實際控制人仍為上海市國資委。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代碼: 02607) 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 * 僅供識別 1 自該等公告日期起，上實國際已根據最新增持計劃增加其在本公司的持股比例。截至本次股 權調整完成時，上實集 ...